☰

Balveen Kaur - Publications

Affiliations: 
Neuroscience Ohio State University, Columbus, Columbus, OH 
Area:
Neuroscience Biology
Tree Info Grants Similar researchers PubMed Report error

203 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Li X, Yan X, Wang Y, Kaur B, Han H, Yu J. The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of Hematology & Oncology. 16: 45. PMID 37131214 DOI: 10.1186/s13045-023-01439-z  0.548
2023 Sahu U, Mullarkey MP, Pei G, Zhao Z, Hong B, Kaur B. oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy. Molecular Therapy Oncolytics. 29: 30-41. PMID 37114074 DOI: 10.1016/j.omto.2023.03.003  0.311
2023 Hong B, Sahu U, Mullarkey MP, Hong E, Pei G, Yan Y, Otani Y, Banasavadi-Siddegowda Y, Fan H, Zhao Z, Yu J, Caligiuri MA, Kaur B. PKR induces TGF-β and limits oncolytic immune therapy. Journal For Immunotherapy of Cancer. 11. PMID 36796878 DOI: 10.1136/jitc-2022-006164  0.62
2023 Swanner J, Shim JS, Rivera-Caraballo KA, Vázquez-Arreguín K, Hong B, Bueso-Perez AJ, Lee TJ, Banasavadi-Siddegowda YK, Kaur B, Yoo JY. esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation. Molecular Therapy Oncolytics. 28: 171-181. PMID 36789106 DOI: 10.1016/j.omto.2023.01.003  0.764
2023 Saini U, Smith BQ, Dorayappan KDP, Yoo JY, Maxwell GL, Kaur B, Konishi I, O'Malley D, Cohn DE, Selvendiran K. Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 16: 38. PMID 36782250 DOI: 10.1186/s13048-023-01111-7  0.544
2022 Saini U, Smith BQ, Dorayappan KDP, Yoo JY, Maxwell GL, Kaur B, Konishi I, O'Malley D, Cohn DE, Selvendiran K. Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus. Journal of Ovarian Research. 15: 130. PMID 36476493 DOI: 10.1186/s13048-022-01054-5  0.554
2022 Tian L, Xu B, Chen Y, Li Z, Wang J, Zhang J, Ma R, Cao S, Hu W, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nature Cancer. PMID 36357700 DOI: 10.1038/s43018-022-00448-0  0.769
2022 Banasavadi-Siddegowda YK, Namagiri S, Otani Y, Sur H, Rivas S, Bryant JP, Shellbourn A, Rock M, Chowdhury A, Lewis CT, Shimizu T, Walbridge S, Kumarasamy S, Shah AH, Lee TJ, ... ... Kaur B, et al. Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. Neuro-Oncology Advances. 4: vdac095. PMID 35875691 DOI: 10.1093/noajnl/vdac095  0.725
2022 Rivera-Caraballo KA, Nair M, Lee TJ, Kaur B, Yoo JY. The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics. Molecular Therapy Oncolytics. 26: 63-75. PMID 35795093 DOI: 10.1016/j.omto.2022.05.013  0.747
2022 Anami Y, Otani Y, Xiong W, Ha SYY, Yamaguchi A, Rivera-Caraballo KA, Zhang N, An Z, Kaur B, Tsuchikama K. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors. Cell Reports. 39: 110839. PMID 35613589 DOI: 10.1016/j.celrep.2022.110839  0.308
2022 Otani Y, Yoo JY, Shimizu T, Kurozumi K, Date I, Kaur B. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Brain Tumor Pathology. PMID 35384530 DOI: 10.1007/s10014-022-00431-8  0.632
2022 Murphy SA, Mapes NJ, Dua D, Kaur B. Histone modifiers at the crossroads of oncolytic and oncogenic viruses. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 35143960 DOI: 10.1016/j.ymthe.2022.02.006  0.374
2022 Hong B, Sahu U, Mullarkey MP, Kaur B. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors. Viruses. 14. PMID 35062322 DOI: 10.3390/v14010118  0.468
2022 Otani Y, Yoo JY, Lewis CT, Chao S, Swanner J, Shimizu T, Kang JM, Murphy SA, Rivera-Caraballo K, Hong B, Glorioso JC, Nakashima H, Lawler SE, Banasavadi-Siddegowda Y, Heiss JD, ... ... Kaur B, et al. NOTCH induced MDSC recruitment after oHSV virotherapy in CNS cancer models modulates anti-tumor immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35022322 DOI: 10.1158/1078-0432.CCR-21-2347  0.808
2021 Tian L, Xu B, Teng KY, Song M, Zhu Z, Chen Y, Wang J, Zhang J, Feng M, Kaur B, Rodriguez-Rodriguez L, Caligiuri MA, Yu J. Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34645647 DOI: 10.1158/1078-0432.CCR-21-1248  0.627
2021 Xu B, Tian L, Chen J, Wang J, Ma R, Dong W, Li A, Zhang J, Antonio Chiocca E, Kaur B, Feng M, Caligiuri MA, Yu J. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nature Communications. 12: 5908. PMID 34625564 DOI: 10.1038/s41467-021-26003-6  0.66
2021 Nair M, Bolyard C, Lee TJ, Kaur B, Yoo JY. Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy. Cancers. 13. PMID 34298774 DOI: 10.3390/cancers13143562  0.845
2021 Yeh M, Wang YY, Yoo JY, Oh C, Otani Y, Kang JM, Park ES, Kim E, Chung S, Jeon YJ, Calin GA, Kaur B, Zhao Z, Lee TJ. MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. Scientific Reports. 11: 9219. PMID 33911148 DOI: 10.1038/s41598-021-88615-8  0.679
2021 Ghose J, Dona A, Murtadha M, Gunes EG, Caserta E, Yoo JY, Russell L, Jaime-Ramirez AC, Barwick BG, Gupta VA, Sanchez JF, Sborov DW, Rosen ST, Krishnan A, Boise LH, ... Kaur B, et al. Oncolytic herpes simplex virus infects myeloma cells and . Molecular Therapy Oncolytics. 20: 519-531. PMID 33738338 DOI: 10.1016/j.omto.2021.02.009  0.637
2021 Park ES, Kim S, Huang S, Yoo JY, Körbelin J, Lee TJ, Kaur B, Dash PK, Chen PR, Kim E. Selective endothelial hyperactivation of oncogenic KRAS induces brain arteriovenous malformations in mice. Annals of Neurology. PMID 33675084 DOI: 10.1002/ana.26059  0.654
2021 Otani Y, Sur H, Rachaiah G, Namagiri S, Chowdhury A, Lewis CT, Shimizu T, Gangaplara A, Wang X, Vézina A, Maric D, Jackson S, Yan Y, Zhengping Z, Ray-Chaudhury A, ... ... Kaur B, et al. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma. Neuro-Oncology. PMID 33556161 DOI: 10.1093/neuonc/noab014  0.605
2020 Yoo JY, Yeh M, Kaur B, Lee TJ. Targeted delivery of small noncoding RNA for glioblastoma. Cancer Letters. PMID 33176185 DOI: 10.1016/j.canlet.2020.11.004  0.655
2020 Kaur B, Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY. Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33087329 DOI: 10.1158/1078-0432.CCR-20-2210  0.602
2020 Glorioso JC, Cohen JB, Goins WF, Hall B, Jackson JW, Kohanbash G, Amankulor N, Kaur B, Caligiuri MA, Chiocca EA, Holland EC, Quéva C. Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology. 41: 381-468. PMID 32938804 DOI: 10.21775/Cimb.041.381  0.756
2020 Duncan RM, Reyes L, Moats K, Robinson RM, Murphy SA, Kaur B, Stessman HAF, Dolloff NG. ATF3 coordinates anti-tumor synergy between epigenetic drugs and protein disulfide isomerase inhibitors. Cancer Research. PMID 32561529 DOI: 10.1158/0008-5472.Can-19-4046  0.472
2020 Lee TJ, Yuan X, Kerr K, Yoo JY, Kim DH, Kaur B, Eltzschig HK. Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury. Pharmacological Reviews. 72: 639-667. PMID 32554488 DOI: 10.1124/Pr.119.019026  0.652
2020 Nair M, Khosla M, Otani Y, Yeh M, Park F, Shimizu T, Kang JM, Bolyard C, Yu JG, Kumar Banasavadi-Siddegowda Y, Lopez G, Kaur B, Pollock RE, Lee TJ, Old M, et al. Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation. Cancers. 12. PMID 32340193 DOI: 10.3390/Cancers12041040  0.855
2020 Thies KA, Hammer AM, Hildreth BE, Steck SA, Spehar JM, Kladney RD, Geisler JM, Das M, Russell LO, Bey JF, Bolyard CM, Pilarski R, Trimboli AJ, Cuitiño MC, Koivisto CS, ... ... Kaur B, et al. Stromal platelet-derived growth factor receptor-β signaling promotes breast cancer metastasis in the brain. Cancer Research. PMID 32327406 DOI: 10.1158/0008-5472.Can-19-3731  0.766
2020 Otani Y, Yoo JY, Chao S, Liu J, Jaime-Ramirez AC, Lee TJ, Hurwitz B, Yan Y, Dai H, Glorioso JC, Caligiuri MA, Yu J, Kaur B. Oncolytic HSV infected glioma cells activate NOTCH in adjacent tumor cells sensitizing tumors to gamma secretase inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32139403 DOI: 10.1158/1078-0432.Ccr-19-3420  0.852
2020 Otani Y, Yoo JY, Chao S, Shimizu T, Lewis C, Murphy S, Pineda J, Caraballo KR, Hong B, Banasavadi-Siddegowda YK, Heiss J, Yan Y, Olson S, Pei G, Zhao Z, ... Kaur B, et al. TAMI-11. IMPACT OF oHSV ACTIVATED NOTCH SIGNALING IN TUMOR MICROENVIRONMENT, AND ITS IMPACT ON ANTI-TUMOR IMMUNITY Neuro-Oncology. 22: ii215-ii215. DOI: 10.1093/neuonc/noaa215.900  0.428
2020 Otani Y, Namagiri S, Thammegowda S, Sur H, Chowdhury A, Lewis C, Shimizu T, Lee TJ, Maric D, Yoo JY, Heiss J, Kaur B, Banasavadi-Siddegowda YK. CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT Neuro-Oncology. 22: ii31-ii31. DOI: 10.1093/neuonc/noaa215.129  0.424
2019 Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy Oncolytics. 15: 214-222. PMID 31890868 DOI: 10.1016/J.Omto.2019.10.005  0.827
2019 McCormack RM, Kaur B. Immune therapy, a double-edged sword for oncolytic viruses. Expert Opinion On Biological Therapy. 1-3. PMID 31382785 DOI: 10.1080/14712598.2019.1650911  0.325
2019 Yeh M, Oh CS, Yoo JY, Kaur B, Lee TJ. Pivotal role of microRNA-138 in human cancers. American Journal of Cancer Research. 9: 1118-1126. PMID 31285946  0.667
2019 Tomita Y, Kurozumi K, Yoo JY, Fuji K, Ichikawa T, Matsumoto Y, Uneda A, Hattori Y, Shimizu T, Otani Y, Oka T, Kaur B, Date I. Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogate glioma invasion via the CCN1 and AKT signaling pathways. Molecular Cancer Therapeutics. PMID 31092561 DOI: 10.1158/1535-7163.Mct-18-0799  0.693
2019 Yoo JY, Swanner J, Otani Y, Nair M, Park F, Banasavadi-Siddegowda Y, Liu J, Jaime-Ramirez AC, Hong B, Geng F, Guo D, Bystry D, Pelphs M, Quadri H, Lee TJ, ... Kaur B, et al. oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Neuro-Oncology. PMID 31063549 DOI: 10.1093/Neuonc/Noz079  0.774
2019 Lee TJ, Nair M, Banasavadi-Siddegowda YK, Liu J, Nallanagulagari T, Jaime-Ramirez AC, Guo JY, Quadri H, Zhang J, Bockhorst KH, Aghi MK, Carbonell WS, Kaur B, Yoo JY. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966. Molecular Cancer Therapeutics. PMID 30926634 DOI: 10.1158/1535-7163.Mct-18-0953  0.788
2019 Hong B, Muili K, Bolyard C, Russell L, Lee TJ, Banasavadi-Siddegowda Y, Yoo JY, Yan Y, Ballester LY, Bockhorst KH, Kaur B. Suppression of HMGB1 Released in the Glioblastoma Tumor Microenvironment Reduces Tumoral Edema. Molecular Therapy Oncolytics. 12: 93-102. PMID 30719499 DOI: 10.1016/J.Omto.2018.11.005  0.844
2019 Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Amendments: Publisher Correction: An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. 37: 102. PMID 30605164 DOI: 10.1038/Nbt0119-102C  0.719
2019 Sizemore G, Hammer A, Thies K, Hildreth B, Russell L, Sizemore S, Trimboli A, Kladney R, Steck S, Das M, Bolyard C, Pilarski R, Schoenfield L, Otero J, Chakravarti A, ... ... Kaur B, et al. Abstract PD9-11: Platelet derived growth factor receptor-β signaling: A novel therapeutic target for breast cancer associated brain metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-11  0.678
2019 Thies K, Hammer A, Hildreth B, Russell L, Sizemore S, Trimboli A, Kladney R, Steck S, Das M, Bolyard C, Pilarski R, Cuitino M, Koivisto C, Schoenfield L, Otero J, ... ... Kaur B, et al. BSCI-11. STROMAL PLATELET DERIVED GROWTH FACTOR RECEPTOR-β (PDGFRβ) PROMOTES BREAST CANCER BRAIN METASTASIS Neuro-Oncology Advances. 1: i3-i3. DOI: 10.1093/noajnl/vdz014.009  0.752
2019 Sur H, Gangaplara A, Wang X, Ray-Chaudhury A, Zhuang Z, Kumar S, Heiss J, Yoo JY, Kaur B, Banasavadi-Siddegowda YK. Stem-16. Dual Inhibition Of Protein Arginine Methyltransferase 5 And Protein Phosphatase 2A Enhances The Anti-Tumor Efficacy In Primary Glioblastoma Neurospheres Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.989  0.362
2019 Otani Y, Young Yoo J, Chao S, Liu J, Cristina Jaime-Ramirez A, Jin Lee T, Hurwitz B, Yan Y, Dai H, Glorioso JC, Caligiuri MA, Yu J, Kaur B. CSIG-23. NOTCH ACTIVATION INDUCED BY HSV-1 ENCODED miRNA-H16 SENSITIZES oHSV-TREATED TUMORS TO NOTCH INHIBITOR Neuro-Oncology. 21: vi49-vi49. DOI: 10.1093/Neuonc/Noz175.193  0.669
2019 Patrizz A, Zorofchain S, Hines G, Takayasu T, Otani Y, Swanner J, Honarpisheh P, Tandon N, Putluri V, Putluri N, Priya Ganesh B, Kaur B, McCullough L, Ballester LY, Esquenazi Y. CBMT-40. THE RELATIONSHIP BETWEEN GLIOMA AND THE GUT-BRAIN AXIS Neuro-Oncology. 21: vi41-vi42. DOI: 10.1093/Neuonc/Noz175.162  0.364
2018 Russell L, Swanner J, Jaime-Ramirez AC, Wang Y, Sprague A, Banasavadi-Siddegowda Y, Yoo JY, Sizemore GM, Kladney R, Zhang J, Lehman NL, Ostrowski MC, Hong B, Caligiuri M, Yu J, ... Kaur B, et al. PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nature Communications. 9: 5006. PMID 30479334 DOI: 10.1038/S41467-018-07344-1  0.778
2018 Xu B, Ma R, Russell L, Yoo JY, Han J, Cui H, Yi P, Zhang J, Nakashima H, Dai H, Chiocca EA, Kaur B, Caligiuri MA, Yu J. An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. Nature Biotechnology. PMID 30475349 DOI: 10.1038/Nbt.4302  0.792
2018 Sizemore ST, Zhang M, Cho JH, Sizemore GM, Hurwitz B, Kaur B, Lehman NL, Ostrowski MC, Robe PA, Miao W, Wang Y, Chakravarti A, Xia F. Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell Research. PMID 30297868 DOI: 10.1038/S41422-018-0086-7  0.361
2018 Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 7: e1486948. PMID 30288349 DOI: 10.1080/2162402X.2018.1486948  0.349
2018 Kim Y, Yoo JY, Lee TJ, Liu J, Yu J, Caligiuri MA, Kaur B, Friedman A. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29686060 DOI: 10.1073/Pnas.1715295115  0.847
2018 Thies KA, Hammer AM, Hildreth BE, Russell LO, Sizemore ST, Trimboli AJ, Kladney RD, Bolyard CM, Pilarski R, Schoenfield L, Otero J, Chakravarti A, Ringel M, Kaur B, Leone G, et al. Abstract 49: Stromal platelet derived growth factor receptor (PDGFRβ) signaling: A novel therapeutic target for breast cancer brain metastasis (BCBM) Tumor Biology. DOI: 10.1158/1538-7445.Am2018-49  0.687
2018 Otani Y, Yoo JY, Lee TJ, Liu J, Jaime-Ramirez AC, Kaur B. CSIG-33. ONCOLYTIC HERPES VIRUS TREATMENT INDUCED NOTCH SIGNALING VIA HSV-1 microRNA H16 AND IT INVOLVED IN TREATMENT RESISTANCE Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.199  0.337
2017 Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, Phelps M, Zhang J, Beattie CE, Baiocchi R, Kaur B. PRMT5 as a druggable target for glioblastoma therapy. Neuro-Oncology. PMID 29106602 DOI: 10.1093/Neuonc/Nox206  0.455
2017 Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, Kumar P, Baiocchi R, Teknos T, Pichiorri F, Kaur B, et al. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Molecular Therapy Oncolytics. 5: 87-96. PMID 28812060 DOI: 10.1016/J.Omto.2017.05.002  0.758
2017 Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity. 47: 159-170.e10. PMID 28723548 DOI: 10.1016/J.Immuni.2017.06.019  0.808
2017 Canella A, Welker AM, Yoo JY, Xu J, Abbas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu JL, Gumin J, Lang FF, Gurcan M, Kaur B, Sampath D, et al. Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28679777 DOI: 10.1158/1078-0432.Ccr-16-3151  0.734
2017 Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK. A novel interaction of PAK4 with PPARγ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene. PMID 28534509 DOI: 10.1038/Onc.2016.261  0.643
2017 Russell L, Bolyard C, Banasavadi-Siddegowda Y, Weiss A, Zhang J, Shakya R, Powell K, Kaur B. Sex as a biological variable in response to temozolomide. Neuro-Oncology. PMID 28379437 DOI: 10.1093/Neuonc/Nox040  0.645
2017 Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. Cell Reports. 18: 1076-1077. PMID 28122233 DOI: 10.1016/J.Celrep.2017.01.016  0.522
2017 Lee TJ, Yoo JY, Shu D, Li H, Zhang J, Yu JG, Jaime-Ramirez AC, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, et al. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28109960 DOI: 10.1016/J.Ymthe.2016.11.016  0.685
2017 Jaime-Ramirez AC, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard-Blessing C, Wojton J, Kaur B. Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide. The Journal of Gene Medicine. PMID 28087981 DOI: 10.1002/Jgm.2942  0.817
2017 Russell L, Sprague A, Jaime-Ramirez AC, Bolyard C, Banasavadi-Siddegowda Y, Yoo J, Wang PY, Cripe T, Kaur B. Abstract 601: Oncolytic and immune effects of RAPTOR: a novel oncolytic Herpes Simplex Virus 1 expressing PTEN-L for brain tumor therapy Cancer Research. 77: 601-601. DOI: 10.1158/1538-7445.Am2017-601  0.797
2017 Saini U, Riley M, Dorayappan KD, Bolyard C, Kaur B, Zingarelli R, Konishi I, Kuppusamy P, Maxwell GL, Cohn DE, Selvendiran K. Abstract 5888: Tmem 205-mediated cisplatin resistance in ovarian clear cell carcinoma (OCCC) is overcome by herpes simplex virus (oHSV)/cisplatin combination therapy Cancer Research. 77: 5888-5888. DOI: 10.1158/1538-7445.Am2017-5888  0.755
2017 Thies KA, Hammer AM, Trimboli AJ, Hildreth BE, Russell LO, Bolyard CM, Kladney RD, Sizemore ST, Pilarski R, Schoenfield L, Otero J, Chakravarti A, Kaur B, Leone G, Ostrowski MC, et al. Abstract 3911: Stromal platelet derived growth factor receptor-beta (PDGFRbeta) promotes breast brain metastasis Cancer Research. 77: 3911-3911. DOI: 10.1158/1538-7445.Am2017-3911  0.663
2017 Wu JPJ, Canella A, Xu J, Lai T, Welker AM, Beattie CE, Nadella V, Timmers C, Kaur B, Jacob N, Sampath D, Puduvalli VK. EXTH-83. TARGETING DNA REPAIR AND SURVIVAL PATHWAYS THROUGH HEAT SHOCK PROTEIN INHIBITION USING AT13387 TO SENSITIZE GLIOMA TO CHEMORADIATION THERAPY Neuro-Oncology. 19: vi91-vi91. DOI: 10.1093/Neuonc/Nox168.373  0.545
2017 Yoo JY, Lee TJ, Liu J, Jaime-Ramirez AC, Weiss A, Russell L, Nallanagulagari T, Zhang J, Kaur B. EXTH-17. MEK KINASE INHIBITOR, TRAMETINIB, SUPPRESSES MACROPHAGE-SECRETED TNF-α ON ONCOLYTIC HSV-1 THERAPY, ENHANCING VIROTHERAPY. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.312  0.311
2017 Tomita Y, Kurozumi K, Shimizu T, Oka T, Otani Y, Ishida J, Fujii K, Kaur B, Tomotsugu I, Date I. P08.60 RAMBO (rapid anti angiogenesis mediated by oncolytic virus) decreased bevacizumab-induced glioma cell invasion Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.249  0.444
2016 Bolyard CM, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith JG, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, ... ... Kaur B, et al. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852701 DOI: 10.1158/1078-0432.Ccr-16-1818  0.785
2016 Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Disease Models & Mechanisms. 9: 1063-5. PMID 27604693 DOI: 10.1242/dmm.027235  0.603
2016 Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D. Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth. Cell Reports. PMID 27477273 DOI: 10.1016/J.Celrep.2016.07.017  0.55
2016 Yoo JY, Jaime-Ramirez AC, Bolyard C, Dai H, Nallanagulagari T, Wojton J, Hurwitz B, Relation T, Yu JG, Lee TJ, Lotze MT, Zhang J, Croce CM, Yu J, Caligiuri MA, ... ... Kaur B, et al. Bortezomib treatment sensitizes oncolytic HSV-1 treated tumors to NK cell immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27390350 DOI: 10.1158/1078-0432.Ccr-16-1003  0.84
2016 Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. PMID 27292260 DOI: 10.1038/Onc.2016.197  0.755
2016 Banasavadi-Siddegowda YK, Russell L, Frair E, Karkhanis VA, Relation T, Yoo JY, Zhang J, Sif S, Imitola J, Baiocchi R, Kaur B. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene. PMID 27292259 DOI: 10.1038/Onc.2016.199  0.406
2016 Geng F, Cheng X, Wu X, Yoo JY, Cheng C, Guo JY, Mo X, Ru P, Hurwitz B, Kim S, Otero J, Puduvalli VK, Lefai E, Ma J, Nakano I, ... ... Kaur B, et al. Inhibition of SOAT1 suppresses glioblastoma growth via blocking SREBP-1-mediated lipogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27281560 DOI: 10.1158/1078-0432.Ccr-15-2973  0.661
2016 Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Oncotargets and Therapy. 9: 2769-2781. PMID 27274273 DOI: 10.2147/Ott.S99242  0.397
2016 Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, Elder JB, Wang QE, He X, Kaur B, Chiocca EA, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. PMID 27050072 DOI: 10.18632/Oncotarget.8526  0.695
2016 Calla NEQ, Miguel RDV, Boyaka PN, Hall-Stoodley L, Kaur B, Trout W, Pavelko SD, Cherpes TL. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection Mucosal Immunology. 9: 1571-1583. PMID 27007679 DOI: 10.1038/Mi.2016.22  0.367
2016 Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, ... Kaur B, et al. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular Cancer Therapeutics. PMID 26809490 DOI: 10.1158/1535-7163.Mct-15-0240-T  0.45
2016 Ghose J, Russell L, Caserta E, Santhanam R, Jaime-Ramirez AC, Viola D, Krishnan A, Hofmeister CC, Kaur B, Pichiorri F. Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma Blood. 128: 4467-4467. DOI: 10.1182/Blood.V128.22.4467.4467  0.5
2016 Thies K, Taffany DA, Mathsyaraja H, Sharma SM, Meisen WH, Liu T, Timmers C, Otero J, Kaur B, Ostrowski MC. Abstract C30: The CSF1-PU.1 pathway in tumor associated macrophages promotes breast cancer growth and progression Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-C30  0.485
2016 Sizemore G, Mathur A, Thies K, Bolyard C, Sizemore S, Kladney R, Trimboli A, Kaur B, Leone G, Ostrowski M. Abstract C28: Platelet-derived growth factor receptor-β (PDGFRβ) in the breast metastatic tumor microenvironment Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-C28  0.745
2016 Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich J, Wanner R, Bixel K, Riley M, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow P, Cohn DE, et al. Abstract LB-036: Elevated STAT3 expression in ovarian tumor ascites regulates invasion and metastasis: a promising therapeutic target Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-036  0.777
2016 Banasavadi-Siddegowda YK, Russell L, Zhang J, Karkhanis VA, Imitola J, Baiocchi R, Kaur B. Abstract 2845: PRMT5-PTEN molecular pathway regulates senescence and self-renewal of Glioblastoma stem-like cells Cancer Research. 76: 2845-2845. DOI: 10.1158/1538-7445.Am2016-2845  0.473
2016 Kesanakurti D, Xu J, Kaur B, Puduvalli V, Canella A. RBIO-06. CROSSTALK OF ErbB2 WITH LEF1 REGULATES JAGGED1-MEDIATED RADIORESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.726  0.554
2016 Carbonell S, Yoo JY, Nallanagulagari T, Jaime-Ramirez AC, Bolyard C, Lee TJ, Zhang J, Croce C, Wu E, Aghi M, Kaur B. EXTH-33. OS2966 DRAMATICALLY ENHANCES PRECLINICAL EFFICACY OF ONCOLYTIC VIRUS THERAPY Neuro-Oncology. 18: vi66-vi66. DOI: 10.1093/Neuonc/Now212.277  0.723
2016 Kesanakurti D, Xu J, Canella A, Jha P, Kaur B, Puduvalli V. Csig-28. Novel Function Of Brachyury As A Potent Regulator Of Hedgehog Signaling And Stemness In Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.189  0.517
2016 Weiss A, Koutras G, Bolyard C, Kaur B. 656. Effects of STAT3 Inhibition on the Innate Immune Response to OV Therapy Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33464-5  0.784
2016 Sette P, Li A, Marzulli M, Leronni D, Zhang M, Goins W, Kaur B, Bolyard C, Amankulor N, Glorioso J, Grandi P. 520. Arming a Tumor Targeted Oncolytic HSV Vector with MMP9 for Enhanced Distribution and Killing Activity Molecular Therapy. 24: S207. DOI: 10.1016/S1525-0016(16)33329-9  0.8
2016 Old M, Jamie-Ramirez C, Yu J, Kumar B, Kumar P, Pan Q, Lee J, Teknos T, Pichiorri F, Kaur B. 415. The Potency of a Histone Deacetylase Inhibitor and Reolysin in Head and Neck Squamous Cell Carcinoma Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33224-5  0.489
2015 Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, Grandi P. Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 99-107. PMID 28142028 DOI: 10.1038/mt.2014.177  0.483
2015 Yoo JY, Yu JG, Kaka A, Pan Q, Kumar P, Kumar B, Zhang J, Mazar A, Teknos TN, Kaur B, Old MO. ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. Molecular Therapy Oncolytics. 2: 15008. PMID 27119105 DOI: 10.1038/Mto.2015.8  0.657
2015 Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Standardized orthotopic xenografts in zebrafish reveal glioma cell line specific characteristics and tumor cell heterogeneity. Disease Models & Mechanisms. PMID 26659251 DOI: 10.1242/Dmm.022921  0.659
2015 Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Research. PMID 26631269 DOI: 10.1158/0008-5472.Can-15-0894  0.772
2015 Cheng C, Ru P, Geng F, Liu J, Yoo JY, Wu X, Cheng X, Euthine V, Hu P, Guo JY, Lefai E, Kaur B, Nohturfft A, Ma J, Chakravarti A, et al. Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. Cancer Cell. 28: 569-81. PMID 26555173 DOI: 10.1016/J.Ccell.2015.09.021  0.56
2015 Wojton J, Meisen WH, Kaur B. How to train glioma cells to die: molecular challenges in cell death. Journal of Neuro-Oncology. PMID 26542029 DOI: 10.1007/S11060-015-1980-1  0.83
2015 Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, et al. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 6: 31134-50. PMID 26429859 DOI: 10.18632/Oncotarget.5290  0.32
2015 Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, ... Kaur B, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports. 5: 11483. PMID 26155832 DOI: 10.1038/Srep11483  0.737
2015 Lee TJ, Haque F, Vieweger M, Yoo JY, Kaur B, Guo P, Croce CM. Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor. Methods in Molecular Biology (Clifton, N.J.). 1297: 137-52. PMID 25896001 DOI: 10.1007/978-1-4939-2562-9_10  0.688
2015 Lee TJ, Haque F, Shu D, Yoo JY, Li H, Yokel RA, Horbinski C, Kim TH, Kim SH, Kwon CH, Nakano I, Kaur B, Guo P, Croce CM. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget. 6: 14766-76. PMID 25885522 DOI: 10.18632/Oncotarget.3632  0.732
2015 Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3274-85. PMID 25829396 DOI: 10.1158/1078-0432.Ccr-14-3118  0.833
2015 Jacobsen K, Russell L, Kaur B, Friedman A. Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model. Bulletin of Mathematical Biology. 77: 984-1012. PMID 25758754 DOI: 10.1007/S11538-015-0074-8  0.655
2015 Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B. Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Molecular Cancer Therapeutics. 14: 307-14. PMID 25376607 DOI: 10.1158/1535-7163.Mct-14-0659  0.382
2015 Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 99-107. PMID 25200130 DOI: 10.1038/Mt.2014.177  0.692
2015 Xilin C, Han J, Jianhong C, Meisen W, Jianying Z, Chiocca EA, Kaur B, Caligiuri MA, Yu J. Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor Blood. 126: 210-210. DOI: 10.1182/Blood.V126.23.210.210  0.765
2015 Meisen WH, Dubin S, Sizemore S, Mathsyaraja H, Thies K, Lehman N, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Ostrowski M, Kaur B. Abstract P6-16-02: Oncolytic viral therapy enhances the survival of mice in a novel model of breast cancer brain metastases Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-16-02  0.373
2015 Yan F, Banasavadi-Siddegowda Y, Patton JT, Lustberg M, Wu X, Kaur B, Baiocchi RA. Abstract LB-218: Protein arginine methyltransferase inhibition of malignant gliomas leads to restored chemokine expression and enhanced immune effector function Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-218  0.468
2015 Canella A, Xu J, Meisen WH, Kaur B, Rizzotto L, Kesanakurti D, Nagarajan P, Puduvalli VK. Abstract 683: DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide Cancer Research. 75: 683-683. DOI: 10.1158/1538-7445.Am2015-683  0.562
2015 Kesanakurti D, Xu J, Canella A, Nagarajan P, Kaur B, Puduvalli VK. Abstract 4158: Novel PAK4-mediated regulation of endothelial CXCL1/CXCR2 signaling and angiogenesis in glioblastoma Cancer Research. 75: 4158-4158. DOI: 10.1158/1538-7445.Am2015-4158  0.677
2015 Li A, Marzulli M, Zhang M, Goins W, Kaur B, Bolyard C, Amankulor N, Leronni D, Sette P, Cohen J, Glorioso J, Grandi P. Abstract 3546: Arming a tumor targeted oncolytic herpes simplex sirus type 1 with matrix metalloproteinase 9 for enhanced vector distribution and killing activity Cancer Research. 75: 3546-3546. DOI: 10.1158/1538-7445.Am2015-3546  0.813
2015 Naidu S, Saini U, ElNaggar AC, Bid HK, Wanner R, Bixel K, Suarez AA, Bolyard C, Kaur B, Goodfellow PJ, Kuppusamy P, Cohn D, Selvendiran K. Abstract 1720: HO-3867, a selective inhibitor of stat3, suppress ovarian tumor growth and metastasis in human tissue culture and in an orthotopic mouse model Cancer Research. 75: 1720-1720. DOI: 10.1158/1538-7445.Am2015-1720  0.722
2015 Sette P, Li A, Marzulli M, Zhang M, Goins W, Kaur B, Bolyard C, Caligiuri M, Cripe T, Chiocca A, Amankulor N, Glorioso J, Grandi P. ATPS-26ONCOLYTIC VECTORS BASED ON HSV FOR TREATMENT OF GBM Neuro-Oncology. 17: v23.4-v23. DOI: 10.1093/Neuonc/Nov204.26  0.816
2015 Canella A, Xu J, Yoo JY, Kaur B, Nagarajan P, Kesanakurti D, Puduvalli VK. Atps-05Characterization Of The Activity Of At13387, A Novel Second Generation Hsp90 Inhibitor Against Gliomas Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov204.05  0.665
2015 Sette P, Marzulli M, Leronni D, Zhang M, Goins W, Kaur B, Chelsea B, Cripe T, Chiocca A, Glorioso J, Amankulor N, Grandi P. 625. Arming a Tumor Targeted Oncolytic Herpes Simplex Virus Type 1 With Matrix Metalloproteinase 9 for Enhanced Vector Distribution and Killing Activity Molecular Therapy. 23: S248. DOI: 10.1016/S1525-0016(16)34234-4  0.658
2015 Currier M, Rizvi T, Nartker B, Chen D, Wang P, Patel A, Chaney K, Streby K, Kaur B, Grandi P, Glorioso J, Antonio Chiocca E, Ecsedy J, Conner J, Ratner N, et al. 432. Aurora A Kinase Inhibition Enhances Oncolytic Herpes Simplex Virotherapy in Models of Neuroblastoma Molecular Therapy. 23: S171. DOI: 10.1016/S1525-0016(16)34041-2  0.541
2014 Suh SS, Yoo JY, Cui R, Kaur B, Huebner K, Lee TK, Aqeilan RI, Croce CM. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs. Plos Genetics. 10: e1004652. PMID 25340791 DOI: 10.1371/Journal.Pgen.1004652  0.596
2014 Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B. Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6479-94. PMID 25294909 DOI: 10.1158/1078-0432.Ccr-14-0463  0.822
2014 Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 5: 9703-9. PMID 25210852 DOI: 10.18632/Oncotarget.2232  0.806
2014 Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Research. 74: 5364-70. PMID 25106428 DOI: 10.1158/0008-5472.Can-14-0386  0.846
2014 Wojton J, Elder J, Kaur B. How efficient are autophagy inhibitors as treatment for glioblastoma? Cns Oncology. 3: 5-7. PMID 25054892 DOI: 10.2217/Cns.13.52  0.837
2014 Kim Y, Lee HG, Dmitrieva N, Kim J, Kaur B, Friedman A. Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model. Plos One. 9: e102499. PMID 25047810 DOI: 10.1371/Journal.Pone.0102499  0.67
2014 Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1678-87. PMID 24895995 DOI: 10.1038/Mt.2014.101  0.853
2014 Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro-Oncology. 16: 1354-64. PMID 24879047 DOI: 10.1093/Neuonc/Nou088  0.564
2014 Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, ... Kaur B, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3787-98. PMID 24815720 DOI: 10.1158/1078-0432.Ccr-14-0553  0.823
2014 Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, ... ... Kaur B, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Research. 74: 1752-65. PMID 24453002 DOI: 10.1158/0008-5472.Can-13-0884  0.823
2014 Banasavadi-Siddegowda YK, Imitola J, Baiocchi R, Kaur B. RM-01 * RADIATION INDUCED PRMT5 EXPRESSION IS REGULATED BY miRNA-96 IN GLIOBLASTOMA Neuro-Oncology. 16: v186-v186. DOI: 10.1093/Neuonc/Nou273.1  0.358
2014 Jaime-Ramirez A, Bolyard C, Meisen W, Dmitrieva N, Banasavadi-Siddegowda Y, Kaur B. Nt-12Impact Of Humanized Chondroitinase Abc On Ov Therapy For Intracranial Tumors. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.12  0.784
2014 Yoo JY, Banasavadi-Siddegowda YY, Relation T, Aghi M, Kaur B. ET-70COMBINATION OF oHSV WITH INTEGRIN β1 NEUTRALIZING ANTIBODY (OS2966) AUGMENTS oHSV THERAPY Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou255.67  0.436
2014 Muili K, Bolyard C, Jaime-Ramirez C, Yoo JY, Kaur B. Et-40Oncolytic Virus Induced Hmgb1 Secretion And Its Impact On Tumor Angiogenesis Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou255.40  0.81
2014 Li A, Marzulli M, Mazzacurati L, Kaur B, Bolyard C, Cohen J, Goins W, Zhang M, Glorioso J, Grandi P. ET-34 * HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA Neuro-Oncology. 16: v87-v87. DOI: 10.1093/Neuonc/Nou255.34  0.789
2014 Kaur B, Meisen WH, Hardcastle J, Wojton J, Wohleb E, Alvarez-Breckenridge C, Pow-anpongkul P, Godbout J. Vstat120 Reduces The Innate Inflammatory Response To Infection And Enhances Oncolytic Viral Therapy For Glioblastoma. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou209.2  0.846
2014 Guo D, Geng F, Aggarwal R, Liu J, Yoo JY, Guo Q, Guo JY, Hurwitz B, Ru P, Cheng C, Joshi K, Ichiro N, Kaur B, Chakravarti A. Interplay Of Lipid Droplets And Autophagy Regulates Glioblastoma Survival Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.31  0.365
2013 Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, Chiocca EA. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5952-9. PMID 24056786 DOI: 10.1158/1078-0432.CCR-12-3588  0.815
2013 Racoma IO, Meisen WH, Wang QE, Kaur B, Wani AA. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. Plos One. 8: e72882. PMID 24039814 DOI: 10.1371/Journal.Pone.0072882  0.437
2013 Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA. STAT3 activation promotes oncolytic HSV1 replication in glioma cells. Plos One. 8: e71932. PMID 23936533 DOI: 10.1371/Journal.Pone.0071932  0.819
2013 Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date I. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Therapy. 20: 437-44. PMID 23827879 DOI: 10.1038/Cgt.2013.38  0.642
2013 Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir EG, Hall RA. Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. The Journal of Biological Chemistry. 288: 22248-56. PMID 23782696 DOI: 10.1074/Jbc.M113.489757  0.563
2013 Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski MC, Kaur B, Qi X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1517-25. PMID 23732993 DOI: 10.1038/Mt.2013.114  0.839
2013 Price RL, Song J, Bingmer K, Kim TH, Yi JY, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Research. 73: 3441-50. PMID 23729642 DOI: 10.1093/Neuonc/Nou206.27  0.721
2013 Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, Date I. Gene expression profiling of the anti-glioma effect of Cilengitide. Springerplus. 2: 160. PMID 23667810 DOI: 10.1186/2193-1801-2-160  0.546
2013 Meisen WH, Kaur B. How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma? Expert Review of Neurotherapeutics. 13: 341-3. PMID 23545048 DOI: 10.1586/Ern.13.25  0.423
2013 Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, ... ... Kaur B, et al. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1014-23. PMID 23481323 DOI: 10.1038/Mt.2013.39  0.817
2013 Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 561-9. PMID 23070115 DOI: 10.1038/Mt.2012.211  0.855
2013 Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date I. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology : Official Journal of the Japanese Society of Neuropathology. 33: 162-74. PMID 22989076 DOI: 10.1111/J.1440-1789.2012.01344.X  0.64
2013 Yan F, Gordon K, Mahasenan K, Lustberg M, Alinari L, Earl CT, Kaur B, Li C, Baiocchi RA. Abstract 4637: Developing a first in class of drug to inhibit protein arginine methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme. Cancer Research. 73: 4637-4637. DOI: 10.1158/1538-7445.Am2013-4637  0.431
2013 Hurwitz BS, Yoo JY, Bolyard C, Yu J, Wojton J, Old M, Kaur B. Abstract 3312: Oncolytic HSV (34.5ENVE) sensitizes bortezomib-induced cancer cell killing through induction of RIP1 dependent necroptosis. Cancer Research. 73: 3312-3312. DOI: 10.1158/1538-7445.Am2013-3312  0.761
2013 Wojton J, Jacob NK, Denton N, Dmitrieva N, Nakashima H, Kwon C, Chow L, Chiocca EA, Chakravarti A, Kaur B, Qi X. Abstract 2169: SapC-DOPS induces lethal mitophagy in glioblastoma. Cancer Research. 73: 2169-2169. DOI: 10.1158/1538-7445.Am2013-2169  0.824
2013 Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, ... ... Kaur B, et al. OMICS AND PROGNSTIC MARKERS Neuro-Oncology. 15: iii136-iii155. DOI: 10.1093/Neuonc/Not183  0.395
2013 Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... Kaur B, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176  0.715
2012 Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18: 1827-34. PMID 23178246 DOI: 10.1038/Nm.3013  0.815
2012 Gatson NN, Chiocca EA, Kaur B. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neuroscience Letters. 527: 62-70. PMID 22906922 DOI: 10.1016/J.Neulet.2012.08.001  0.619
2012 Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. Extracellular vesicles and their convergence with viral pathways. Advances in Virology. 2012: 767694. PMID 22888349 DOI: 10.1155/2012/767694  0.361
2012 Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4931-41. PMID 22753591 DOI: 10.1158/1078-0432.Ccr-12-0697  0.824
2012 Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakàcs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America. 109: 5316-21. PMID 22431589 DOI: 10.1073/Pnas.1202465109  0.665
2012 Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH, Sandberg EM, Kaluz S, Van Meir EG. A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1. Oncogene. 31: 5144-52. PMID 22330140 DOI: 10.1038/Onc.2012.1  0.824
2012 Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, Ha YP, Bergin S, Hwang C, Fernandez SA, Kaur B, Caligiuri MA, Chiocca EA. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. Journal of Virology. 86: 4566-77. PMID 22318143 DOI: 10.1128/Jvi.05545-11  0.828
2012 Alvarez-Breckenridge CA, Yu J, Kaur B, Caligiuri MA, Chiocca EA. Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology. 2012: 702839. PMID 22312364 DOI: 10.1155/2012/702839  0.817
2012 Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso JC, Caligiuri MA, Kaur B. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research. 72: 1353-62. PMID 22282654 DOI: 10.1158/0008-5472.Can-11-2526  0.816
2012 Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 287-97. PMID 22031239 DOI: 10.1038/Mt.2011.208  0.845
2012 Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Current Pharmaceutical Biotechnology. 13: 1842-51. PMID 21740359 DOI: 10.2174/138920112800958814  0.549
2012 Okemoto K, Wagner BP, Haseley AM, Price RL, Kaur B, Chiocca AE. Abstract 4080: 5-Azacitydine augments the anti-glioma efficacy of Herpes-based oncolytic virotherapy Cancer Research. 72: 4080-4080. DOI: 10.1158/1538-7445.Am2012-4080  0.8
2012 Yang FH, Zhang B, Zhou DJ, Bie L, Tom MW, Drummond DC, Nicolaides T, Mueller S, Banerjee A, Park JW, Prados MD, James DC, Gupta N, Hashizume R, Strohbehn GW, ... ... Kaur B, ... ... Kaur B, ... ... Kaur B, et al. LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 14: vi25-vi37. DOI: 10.1093/Neuonc/Nos222  0.775
2011 Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, Grecula J, Newton H, Harris KS, Grossman RG, Trask TW, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3611-9. PMID 21844505 DOI: 10.1200/Jco.2011.35.5222  0.813
2011 Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, Kaur B, Fernandez SA, Chiocca EA, Lawler SE. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Research. 71: 5374-80. PMID 21697283 DOI: 10.1158/0008-5472.Can-10-3026  0.631
2011 Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC, Kaur B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1362-72. PMID 21177410 DOI: 10.1158/1078-0432.Ccr-10-2213  0.718
2011 Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Kaur B, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158  0.711
2010 Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine & Growth Factor Reviews. 21: 127-34. PMID 20399700 DOI: 10.1016/J.Cytogfr.2010.02.014  0.849
2010 Nakashima H, Kaur B, Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & Growth Factor Reviews. 21: 119-26. PMID 20226717 DOI: 10.1016/J.Cytogfr.2010.02.004  0.636
2010 Klenotic PA, Huang P, Palomo J, Kaur B, Van Meir EG, Vogelbaum MA, Febbraio M, Gladson CL, Silverstein RL. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. The American Journal of Pathology. 176: 2039-50. PMID 20167858 DOI: 10.2353/Ajpath.2010.090782  0.679
2010 Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1 Molecular Therapy. 18: 285-294. PMID 19844198 DOI: 10.1038/Mt.2009.232  0.857
2010 Cork S, Sandberg EM, Kaur B, Mao H, Zhang Z, Olson J, Meir EGV. Abstract 3433: A furin/MMP-14 signaling cascade processes BAI1 into a novel secreted anti-angiogenic and anti-tumorigenic factor, Vasculostatin-40 (Vstat40) Cancer Research. 70: 3433-3433. DOI: 10.1158/1538-7445.Am10-3433  0.77
2010 Yan F, Alinari L, Lustberg M, Martin LK, Nowicki O, Wu X, Yu B, Gordon K, Wolfson A, Ryu J, Kaur B, Kwon C, Lawler S, Nuovo G, Liu S, et al. Abstract 1584: Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas Cancer Research. 70: 1584-1584. DOI: 10.1158/1538-7445.Am10-1584  0.597
2010 Alvarez-Breckenridge CA, Yu J, Pradarelli J, Liu T, Kaur B, Caligiuri M, Chiocca EA. Abstract 1514: Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation Cancer Research. 70: 1514-1514. DOI: 10.1158/1538-7445.Am10-1514  0.797
2010 Haseley A, Boone S, Kurozumi K, Kaur B. Abstract 1505: The effect of Cyr61 on oncolytic HSV-1 therapy for glioblastoma multiforme Cancer Research. 70: 1505-1505. DOI: 10.1158/1538-7445.Am10-1505  0.857
2010 Kaka A, Pradarelli JC, Alvarez-Breckenridge C, Yoo JY, Pan Q, Chiocca EA, Old M, Teknos T, Kaur B. Abstract 1383: The effect of a novel angiogenesis inhibitor (TM) on the efficacy of HSV-1 oncolytic virus Cancer Research. 70: 1383-1383. DOI: 10.1158/1538-7445.Am10-1383  0.781
2009 Kaur B, Cripe TP, Chiocca EA. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy. 9: 341-55. PMID 19860649 DOI: 10.2174/156652309789753329  0.66
2009 Alvarez-Breckenridge C, Kaur B, Chiocca EA. Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical Reviews. 109: 3125-40. PMID 19462957 DOI: 10.1021/Cr900048K  0.791
2009 Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of Neuro-Oncology. 94: 299-312. PMID 19381449 DOI: 10.1007/S11060-009-9875-7  0.452
2009 Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, Van Meir EG. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Research. 69: 1212-20. PMID 19176395 DOI: 10.1158/0008-5472.Can-08-1166  0.827
2009 Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B. Advances in oncolytic virus therapy for glioma. Recent Patents On Cns Drug Discovery. 4: 1-13. PMID 19149710 DOI: 10.2174/157488909787002573  0.852
2008 Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, Chiocca EA, Kaur B. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1382-91. PMID 18545226 DOI: 10.1038/Mt.2008.112  0.851
2007 Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. Journal of the National Cancer Institute. 99: 1768-81. PMID 18042934 DOI: 10.1093/Jnci/Djm229  0.827
2007 Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Rachamimov AS, et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Research. 67: 9398-406. PMID 17909049 DOI: 10.1158/0008-5472.Can-07-1063  0.565
2007 Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Current Cancer Drug Targets. 7: 181-9. PMID 17346110 DOI: 10.2174/156800907780058880  0.842
2007 Kaur B, Chiocca EA. Personalizing oncolytic virotherapy? Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 6-7. PMID 17164767 DOI: 10.1038/Sj.Mt.6300056  0.565
2007 Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, Rooijen NV, Stemmer-Rachamimov AO, Hochberg FH, et al. Erratum: Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses (Cancer Research (2007) 67, (9398-9406)) Cancer Research. 67. DOI: 10.1158/0008-5472.Can-67-22-Cor  0.399
2006 Kaur B, Chiocca EA. Oncolytic viruses: extreme treatment for an extreme disease. Future Microbiology. 1: 351-3. PMID 17661625 DOI: 10.2217/17460913.1.4.351  0.568
2006 Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, Vandertop WP, van Beusechem VW, Dirven CM, Chiocca EA. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 779-88. PMID 16996314 DOI: 10.1016/J.Ymthe.2006.08.008  0.577
2006 Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America. 103: 12873-8. PMID 16908838 DOI: 10.1073/Pnas.0605496103  0.751
2006 Cutter JL, Kurozumi K, Chiocca EA, Kaur B. Gene therapeutics: the future of brain tumor therapy? Expert Review of Anticancer Therapy. 6: 1053-64. PMID 16831077 DOI: 10.1586/14737140.6.7.1053  0.625
2006 Kurozumi K, Cutter J, Carson W, Yang M, Christoforidis G, Chiocca AE, Kaur B. 302. Anti-Angiogenic Treatment Enhances Anti- Tumor Effects of an Oncolytic Virus in an Experimental Rat Glioma Model Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.357  0.514
2005 Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology. 7: 134-53. PMID 15831232 DOI: 10.1215/S1152851704001115  0.801
2005 Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene. 24: 3632-42. PMID 15782143 DOI: 10.1038/Sj.Onc.1208317  0.658
2004 Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. Journal of Neuro-Oncology. 70: 229-43. PMID 15674480 DOI: 10.1007/S11060-004-2752-5  0.638
2004 Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8603-12. PMID 15623644 DOI: 10.1158/1078-0432.Ccr-04-1432  0.727
2004 Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Van Meir EG. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Research. 64: 920-7. PMID 14871821 DOI: 10.1158/0008-5472.Can-03-2073  0.656
2003 Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. The American Journal of Pathology. 162: 19-27. PMID 12507886 DOI: 10.1016/S0002-9440(10)63794-7  0.636
2003 Brat DJ, Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Frontiers in Bioscience : a Journal and Virtual Library. 8: d100-16. PMID 12456339  0.583
2002 Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, Van Meir EG. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Research. 62: 2897-905. PMID 12019170  0.531
2002 Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Research. 62: 2478-82. PMID 11980636  0.511
2002 Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Advances in Anatomic Pathology. 9: 24-36. PMID 11756757 DOI: 10.1097/00125480-200201000-00004  0.582
2000 Kaur B, Doetsch PW. Ultraviolet damage endonuclease (Uve1p): A structure and strand-specific DNA endonuclease Biochemistry. 39: 5788-5796. PMID 10801329 DOI: 10.1021/Bi000189R  0.537
1999 Kaur B, Fraser JL, Freyer GA, Davey S, Doetsch PW. A Uve1p-mediated mismatch repair pathway in Schizosaccharomyces pombe. Molecular and Cellular Biology. 19: 4703-10. PMID 10373519 DOI: 10.1128/Mcb.19.7.4703  0.543
1999 Avery AM, Kaur B, Taylor JS, Mello JA, Essigmann JM, Doetsch PW. Substrate specificity of ultraviolet DNA endonuclease (UVDE/Uve1p) from Schizosaccharomyces pombe. Nucleic Acids Research. 27: 2256-64. PMID 10325412 DOI: 10.1093/Nar/27.11.2256  0.534
1998 Kaur B, Avery AM, Doetsch PW. Expression, purification, and characterization of ultraviolet DNA endonuclease from Schizosaccharomyces pombe Biochemistry. 37: 11599-11604. PMID 9708997 DOI: 10.1021/Bi981008C  0.538
Show low-probability matches.